# Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

> **NCT04796441** · NA · UNKNOWN · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- AML

## Interventions

- **BIOLOGICAL:** CAR-γδT

## Key facts

- **NCT ID:** NCT04796441
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-16
- **Primary completion:** 2021-12-16
- **Final completion:** 2022-02-16
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2021-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04796441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04796441, "Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04796441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*